New Elite Feature: Personalize Your Finviz Homepage

Galectin Therapeutics Inc.

Contributing Author

Recent Articles by Galectin Therapeutics Inc.

May-27	Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis GALT GlobeNewswire
May-15	Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update GALT -7.66% GlobeNewswire
May-11	Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology GALT +5.24% GlobeNewswire
Mar-31	Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update GALT +8.56% GlobeNewswire
Mar-17	Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. GALT GlobeNewswire
Feb-26	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET GALT -5.10% GALT GlobeNewswire
Dec-19	Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 GALT -28.90% GlobeNewswire
Nov-14	Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update GALT GlobeNewswire
Nov-10	Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting GALT GlobeNewswire
Oct-20	Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference GALT GlobeNewswire
Oct-07	Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 GALT +7.43% GlobeNewswire
Sep-02	Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference GALT GlobeNewswire
Aug-14	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update GALT GlobeNewswire
Jul-09	Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 GALT +7.66% GlobeNewswire
Jun-10	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension GALT GlobeNewswire
May-15	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update GALT GlobeNewswire
May-12	Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress GALT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)